NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Odds for success would improve dramatically in their favor, in my opinion, if they could combine with an agent that combats immunosuppression. --RK

Intratumoral injection of activated, autologous dendritic cells is safe and feasible. The accumulation of immune cells in tumor biopsies suggests that these injections have the potential to successfully change the tumor microenvironment from immunosuppressive to one that is conducive to the induction of anti-tumor immune responses. (boy is there alot of good info on dc vaccines overcoming an immunosuppressive environment all by themselvessmile) Normalization of the CD4:CD8 T cell ratio in circulation demonstrates the potential for systemic effects of this novel therapeutic approach.

Rk, do you ever take any accountability for the numerous unsubstantiated, unfounded, speculatory, midleading posts that can easily be disproved? You stated Direct is a monotherapy or won't be used as a combo therapy, right? That was a tough one to disprove. Sure would be nice to see you post something new. -- HGWM

Accountability for what? Show me a post where you disproved me? I'm sorry to disappoint you, but the patent pursuit I shared relates to this pre-clinical GBM combination study:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108219415&txt2find=pd1

You're speculating that DCVax Direct will partner with a CI, based on this:

The findings from the Phase I trial also open the door for potential combination therapy of DCVax-Direct with checkpoint inhibitors. -- NWBT

Your interpretation of the line above is that they're in negotiations? If so, I disagree. We have yet to be told of any on-going negotiations. When I see that line, to me it means the company is trying to find a partner. I believe in order to partner today, big Pharma will need to see strong Direct data, and given most patients failed the vaccine sometime between week 2 and week 4, in my view the Company does not have it. You believe the Direct data is strong the way it is, since majority of patients are alive. We have differences of opinion on the Direct data. What I don’t understand is how you perceive me to be misleading everyone when I share my opinions. Yet, you don't perceive yourself as misleading anyone when you share your opinions. Doesn’t seem right.

The current DCVax Direct study is a mono-therapy because that is what the Phase I/II study is. That is the regulator path that it is on. I can't evaluate Direct as a combo-therapy as it is not one. There is no active study posted on NCT with a checkpoint inhibitor. You're convinced the company will pursue a CI study. I am convinced that if they partner with big Pharma checkpoint, it will be due to strong DCVax results, and since they don't have them yet, they will need to wait. One of us will be correct. But for now, at this point in time, a CI partnership talk(s) is speculative. You can continue to disagree.